Antwerp Hospital Network (ZNA) Cadix

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Myeloproliferative neoplasms

Running trials

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source

  Contact: John Mei

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myeloproliferative neoplasms1 recruiting